Randomized (N=41)
No dose Doripenem (n=0) Meropenem (n=0)
Intention-to-treat (n=31)
Treated with IV therapy only (n=9)
Treated with IV and oral therapy (n=22) o Did not complete oral therapy
(n=2)
Abdominal pain (n=1)
Other (n=1)
Did not complete study (n=0) Allocated to doripenem (n=31)
Intention-to-treat (n=10)
Treated with IV therapy only (n=2)
Treated with IV and oral therapy (n=6)
Did not complete study (n=2) o Withdrew consent (n=1)
o Unable to adhere to study protocol (n=1)
Allocated to meropenem (n=10)
Complicated intra-abdominal infection study
Randomized (N=41)
No dose Doripenem (n=1) Cefepime (n=0)
Intention-to-treat (n=30)
Treated with IV therapy only (n=4) o Did not complete (n=3)
Did not have a study- qualifying infection (n=2)
No growth in urine sample (n=1)
Treated with IV and oral therapy (n=26) Allocated to doripenem (n=30)
Intention-to-treat (n=10)
Treated with IV therapy only (n=2)
Treated with IV and oral therapy (n=8)
Did not complete study (n=0) Allocated to cefepime (n=10)
Complicated urinary tract infection study
Randomized (N=7)
No dose Doripenem (n=0) Cefepime (n=0)
Intention-to-treat (n=5)
Treated with IV therapy only (n=2) o Did not complete: Adverse event
(n=1)*
Treated with IV and oral therapy (n=3)
Did not complete study (n=0) Allocated to doripenem (n=5)
Intention-to-treat (n=2)
Treated with IV therapy only (n=0)
Treated with IV and oral therapy (n=2)
Did not complete study (n=0) Allocated to cefepime (n=2)
*Discontinued treatment with study drug due to empyema, but completed the study.
